Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial
Testing different doses of Exemestane in women with early breast cancer (MDA2014-04-01)
Sponsor: MD Anderson Cancer Center
Enrolling: Female Patients Only
IRB Number: AAAQ5054
U.S. Govt. ID: NCT02598557
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This randomized phase IIb trial studies how well alternative dosing of exemestane before surgery works in treating postmenopausal patients with stage 0-II estrogen positive breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of exemestane may treat early stage (stage 0-II) breast cancer. Comparing the exemestane standard dose regimen versus two alternative, less frequent dose regimens may decrease undesirable symptoms and be more effective in treating breast cancer.
This study is closed
Investigator
Katherine Crew, MD
Do You Qualify?
Are you postmenopausal? Or, have you had bilateral oophorectomy or hysterectomy? Yes No
Do you have plans to receive neoadjuvant therapy? Yes No
Do you have severe ostereoporosis? Yes No
Do you have a vertebral fracture? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE